Evidence map›Paper›PMID 38996914›Full record

ArticleJournal of thrombosis and haemostasis : JTH2024

R1205H (Vicenza) causes conformational changes in the von Willebrand factor D'D3 domains and enhances von Willebrand factor binding to clearance receptors LRP1 and SR-AI.

Ferdows Atiq, Orla Rawley, Jamie M O'Sullivan, Mehmet Özbil, Dearbhla Doherty, Niamh Cooke, Virginie Terraube, Alain Chion, Aamir Amin, Anne-Marije Hulshof and 5 more

Abstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ferdows AtiqIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Orla RawleyDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
Jamie M O'SullivanIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Mehmet ÖzbilComputational Biochemistry Group, Gebze Technical University, Institute of Biotechnology, Gebze, Kocaeli, Turkey.
Dearbhla DohertyIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Niamh CookeBioMedicine Design, Pfizer, Grange Castle, Dublin, Ireland.
Virginie TerraubeBioMedicine Design, Pfizer, Grange Castle, Dublin, Ireland.
Alain ChionIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Aamir AminIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Anne-Marije HulshofIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Bogdan BaciIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Ciara ByrneIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Hanan E AburawiIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
David LillicrapDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
James S O'DonnellIrish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland; National Coagulation Centre, St James's Hospital, Dublin, Ireland. Electronic address: jamesodonnell@rcsi.ie.

Funding

Zimmerman Program for the Molecular and Clinical Biology of VWDP01HL081588 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2005 to 2016
$19.3M
Zimmerman Program on the Biology of VWDP01HL144457 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2019 to 2023
$13.3M
NHLBI NIH HHS P01 HL081588NHLBI NIH HHS P01 HL144457
6 · The paper itself

Abstract

backgroundvon Willebrand factor (VWF)-R1205H variant (Vicenza) results in markedly enhanced VWF clearance in humans that has been shown to be largely macrophage-mediated. However, the biological mechanisms underlying this enhanced clearance remain poorly understood.

objectivesThis study aimed to investigate the roles of (i) specific VWF domains and (ii) different macrophage receptors in regulating enhanced VWF-R1205H clearance.

methodsIn vivo clearance of full-length and truncated wild-type (WT)-VWF and VWF with R1205 substitutions was investigated in VWF

resultsIn full-length VWF missing the A1 domain, introduction of R1205H led to significantly enhanced clearance in VWF

conclusionDisruption of the positive charge at amino acid R1205 causes conformational changes in the VWF-D'D3 domains and triggers enhanced LRP1-mediated and SR-AI-mediated clearance.

Indexed as

Low Density Lipoprotein Receptor-Related Protein-1Protein BindingProtein Domainsvon Willebrand FactorAnimalsHumansMacrophagesMiceMice, Inbred C57BLMice, KnockoutProtein ConformationScavenger Receptors, Class BLow Density Lipoprotein Receptor-Related Protein-1Lrp1 protein, mouseScarb1 protein, mouseScavenger Receptors, Class Bvon Willebrand Factorenhanced VWF clearancetype 1C VWDvon Willebrand diseasevon Willebrand factorVWF-R1205H (Vicenza)

Identifiers

PMID38996914
PMCPMC11533894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.